Surgical resection of metastatic melanoma in the era of immunotherapy and targeted therapy. (March 2017)

• Record Type: Journal Article
• Authors: Tyrell, Richard; Antia, Camila; Stanley, Sharon; Deutsch, Gary B
• Is Part Of: Melanoma management. Volume 4:Number 1(2017)
• Page Start: 61
• Page End: 68
• Publication Date: 2017-03
• Subjects: BRAF -- CTLA-4 -- immune -- immunotherapy -- MEK -- melanoma -- metastasectomy -- metastatic -- PD-1 -- surgical therapy; Melanoma -- Periodicals; 616.99477005
• DOI: 10.2217/mmt-2016-0018
• Languages: English
• ISSNs: 2045-0885

Abstract

Melanoma is the deadliest form of skin cancer and one of the few malignancies whose incidence is on the rise. The treatment of metastatic melanoma continues to be quite challenging, although in recent years, there has been significant progress. Current National Comprehensive Cancer Network guidelines list immunotherapy, chemotherapy, surgery and clinical trials as potential options for patients with metastatic disease but do not clearly recommend which is superior. Additionally, when utilizing combined modality treatment there are no clear guidelines for the optimal timing of surgery in the treatment of metastatic melanoma. In this paper we sought to compile the current evidence and on-going trials in order to provide a comprehensive review of the different options available and underway in regards to the treatment of metastatic melanoma. It is clear that with the responses now seen with systemic immunotherapies and targeted therapies, an expanded role for surgery is the logical next step.